Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine (NASDAQ:IRON) announced it will host a conference call on November 4, 2024, at 8:00 am EST to discuss feedback from its end-of-Phase 2 meeting with the FDA regarding bitopertin for Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will make the call available through registration on their investor relations website.
Disc Medicine (NASDAQ:IRON) ha annunciato che terrà una conferenza telefonica il 4 novembre 2024, alle 8:00 EST, per discutere il feedback ricevuto dal suo incontro di fine Fase 2 con la FDA riguardo bitopertin per la Porfiria Eritropoietica Protoporfirica (EPP). L’azienda, che si concentra sullo sviluppo di trattamenti per malattie ematologiche gravi, renderà la chiamata disponibile tramite registrazione sul proprio sito web delle relazioni con gli investitori.
Disc Medicine (NASDAQ:IRON) anunció que celebrará una conferencia telefónica el 4 de noviembre de 2024, a las 8:00 a.m. EST para discutir los comentarios de su reunión de fin de Fase 2 con la FDA sobre bitopertin para la Porfiria Eritropoietica Protoporfírica (EPP). La compañía, que se centra en el desarrollo de tratamientos para enfermedades hematológicas graves, hará que la llamada esté disponible a través del registro en su sitio web de relaciones con inversionistas.
Disc Medicine (NASDAQ:IRON)는 2024년 11월 4일 오전 8시 EST에 FDA와의 제2상 종료 미팅에 대한 피드백에 대해 논의하기 위해 컨퍼런스 콜을 개최한다고 발표했습니다. 심각한 혈액 질환 치료 개발에 집중하는 이 회사는 투자자 관계 웹사이트를 통해 등록 후 전화를 이용할 수 있도록 할 것입니다.
Disc Medicine (NASDAQ:IRON) a annoncé qu'elle tiendra une conférence téléphonique le 4 novembre 2024 à 8h00 EST pour discuter des retours de sa réunion de fin de Phase 2 avec la FDA concernant le bitopertin pour la Porphyrie Protoporphérique Érythropoïétique (EPP). L'entreprise, qui se concentre sur le développement de traitements pour des maladies hématologiques graves, rendra l'appel disponible par le biais d'une inscription sur son site web des relations avec les investisseurs.
Disc Medicine (NASDAQ:IRON) gab bekannt, dass am 4. November 2024 um 8:00 Uhr EST eine Telefonkonferenz stattfinden wird, um das Feedback aus ihrem Treffen am Ende der Phase 2 mit der FDA bezüglich Bitopertin für die Erythropoietische Protoporphyrie (EPP) zu besprechen. Das Unternehmen, das sich auf die Entwicklung von Therapien für schwere hämatologische Erkrankungen konzentriert, wird die Konferenz nach Registrierung auf seiner Investor-Relations-Website verfügbar machen.
- Company completed End of Phase 2 FDA meeting for bitopertin in EPP, indicating progress in clinical development
- Advancement to discussion of Phase 3 plans suggests positive Phase 2 outcomes
- None.
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST.
Conference Call Information
Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com/.
About Bitopertin
Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, and an open-label extension HELIOS trial.
Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.
About Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Erythropoietic protoporphyria (EPP) and X-linked Protoporphyria (XLP) are rare, debilitating and potentially life-threatening diseases caused by mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate called protoporphyrin IX (PPIX). This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain, edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in 20
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
When is Disc Medicine's conference call to discuss FDA feedback for bitopertin?
What is the purpose of IRON's end-of-Phase 2 FDA meeting?